Here are the top stories on Healio.com/OSN this past week:
FDA approves Dextenza for treatment of postoperative ocular pain
Dextenza (dexamethasone ophthalmic insert 0.4 mg) is the first FDA-approved intracanalicular insert to deliver dexamethasone to treat postoperative ocular pain for up to 30 days with one treatment. Read more.
IND application accepted for CRISPR genome editing treatment for LCA10
The FDA has accepted an investigational new drug application for Editas Medicine’s experimental CRISPR genome editing medicine for the treatment of Leber congenital amaurosis type
Uncategorized